CNB Bank Sells 3,701 Shares of Pfizer Inc. (NYSE:PFE)

CNB Bank lessened its stake in Pfizer Inc. (NYSE:PFE) by 7.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 43,544 shares of the biopharmaceutical company’s stock after selling 3,701 shares during the period. CNB Bank’s holdings in Pfizer were worth $1,155,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Bradley Foster & Sargent Inc. CT boosted its position in Pfizer by 3.2% in the second quarter. Bradley Foster & Sargent Inc. CT now owns 271,120 shares of the biopharmaceutical company’s stock worth $7,586,000 after purchasing an additional 8,375 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in shares of Pfizer by 0.6% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 897,017 shares of the biopharmaceutical company’s stock worth $25,099,000 after purchasing an additional 5,246 shares during the period. Meiji Yasuda Asset Management Co Ltd. boosted its holdings in shares of Pfizer by 1.4% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 190,811 shares of the biopharmaceutical company’s stock worth $5,339,000 after buying an additional 2,572 shares during the last quarter. Blair William & Co. IL grew its position in Pfizer by 85.9% during the second quarter. Blair William & Co. IL now owns 1,953,310 shares of the biopharmaceutical company’s stock valued at $54,654,000 after buying an additional 902,376 shares during the period. Finally, Sienna Gestion increased its holdings in Pfizer by 0.8% during the second quarter. Sienna Gestion now owns 221,295 shares of the biopharmaceutical company’s stock valued at $6,189,000 after buying an additional 1,771 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Trading Down 0.0 %

Shares of Pfizer stock opened at $26.49 on Friday. The firm’s 50 day simple moving average is $26.11 and its two-hundred day simple moving average is $28.01. The firm has a market capitalization of $150.09 billion, a price-to-earnings ratio of 35.86, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the prior year, the firm earned ($0.17) EPS. The firm’s revenue was up 31.2% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.49%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 227.03%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on PFE. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.